thalidomide has been researched along with Lupus Erythematosus, Cutaneous in 58 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lupus Erythematosus, Cutaneous: A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 7.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum." | 5.12 | Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007) |
| "St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant dermatoses." | 3.71 | Thalidomide experience of a major Australian teaching hospital. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2002) |
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 3.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal." | 2.77 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. ( Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M, 2012) |
| "Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE)." | 2.72 | Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. ( Aikawa, NE; Bonfa, E; Heise, CO; Pasoto, SG; Romiti, R; Silva, CA; Yuki, EFN, 2021) |
| "Thalidomide has subsequently been reported to be effective in treating a number of dermatoses, including cutaneous lupus erythematosus." | 2.69 | American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. ( Duong, DJ; Gaspari, AA; Moxley, RT; Spigel, GT, 1999) |
| "Thalidomide has shown excellent results for severe cutaneous lupus erythematosus (CLE), but its prescription is limited by potentially severe adverse events." | 2.58 | Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( Arnaud, L; Barbaud, A; Cesbron, E; Chasset, F; Francès, C; Tounsi, T, 2018) |
| "Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "This paper reviews the latest treatments for cutaneous lupus erythematosus." | 2.42 | Update on the management of cutaneous lupus erythematosus. ( Callen, JP, 2004) |
| "Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry." | 1.62 | One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. ( Aikawa, NE; Arnone, M; Bonfa, E; Heise, CO; Kupa, LVK; Pasoto, SG; Pedrosa, TDN; Romiti, R; Silva, CAAD; Soares, R; Yuki, EFN, 2021) |
| "Psychiatric and personality disorders have been extensively documented in patients with systemic lupus erythematosus (SLE)." | 1.46 | High Prevalence of Personality Disorders in Skin-restricted Lupus Patients. ( Bonnefond, S; Collange, M; D'Incan, M; Jalenques, I; Labeille, B; Massoubre, C; Mulliez, A; Perrot, JL; Rondepierre, F; Schwan, R, 2017) |
| "Lenalidomide was well tolerated." | 1.46 | Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. ( Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY, 2017) |
| "Lenalidomide was effective for the treatment of CLE (particularly DLE) but not for the treatment of lupus panniculitis in this series." | 1.43 | Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. ( Davis, MD; Kindle, SA; Pittelkow, MR; Sciallis, GF; Wetter, DA, 2016) |
| "Clinical relapse was frequent (73%) and occurred between 3 and 24 weeks after withdrawal of thalidomide." | 1.42 | Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? ( Baret, I; De Haes, P, 2015) |
| "Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE)." | 1.38 | Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. ( Braunstein, I; Goodman, NG; Kovarik, CL; Krathen, M; Luning Prak, E; Okawa, J; Rosenbach, M; Shah, A; Werth, VP, 2012) |
| "Clinical relapse was frequent (70%) and usually occurred 5 months after withdrawal or reduction of thalidomide." | 1.38 | Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. ( Castro-Marrero, J; Cortés-Hernández, J; Ordi-Ros, J; Torres-Salido, M; Vilardell-Tarres, M, 2012) |
| " The threshold neurotoxic dosage is lower than previously reported." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
| "Thalidomide has been reported as an effective treatment in at least 200 cases of severe DLE." | 1.33 | [Thalidomide therapy for discoid lupus erythematosus]. ( Baum, S; Lyakhovisky, A; Salomon, M; Shpiro, D; Trau, H, 2006) |
| "Thalidomide is an anti-inflammatory agent and an immunomodulator that inhibits the production of tumor necrosis factor alpha." | 1.32 | Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. ( Fleischer, AB; Grummer, SE; Housman, TS; Jorizzo, JL; McCarty, MA; Sutej, PG, 2003) |
| "Its use in cutaneous lupus erythematosus is now well documented, although most groups favour high-dose regimes (200 mg twice daily), where side effects are common and may limit drug use." | 1.31 | Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus. ( Goodfield, MJ; Thomson, KF, 2001) |
| "Thalidomide is a potent anti-inflammatory drug in patients with SLE and cutaneous LE, possibly interacting with the recruitment of lymphocytes." | 1.31 | Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. ( Messer, G; Meurer, M; Plewig, G; Walchner, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.17) | 18.2507 |
| 2000's | 25 (43.10) | 29.6817 |
| 2010's | 23 (39.66) | 24.3611 |
| 2020's | 7 (12.07) | 2.80 |
| Authors | Studies |
|---|---|
| Rizvi, SK | 1 |
| Chong, BF | 1 |
| Sherman, MA | 1 |
| Srinivasalu, H | 1 |
| Kirkorian, AY | 1 |
| Cardis, MA | 1 |
| Tsiogka, A | 1 |
| Gerochristou, M | 1 |
| Agrogianni, A | 1 |
| Gregoriou, S | 1 |
| Rigopoulos, D | 1 |
| Kontochristopoulos, G | 1 |
| Wang, X | 2 |
| Li, M | 1 |
| Zeng, X | 1 |
| Wang, Q | 1 |
| Yuki, EFN | 2 |
| Silva, CA | 1 |
| Aikawa, NE | 2 |
| Romiti, R | 2 |
| Heise, CO | 2 |
| Bonfa, E | 2 |
| Pasoto, SG | 2 |
| Reymann, V | 1 |
| Bessis, D | 2 |
| Bergeret, B | 1 |
| Lipsker, D | 2 |
| Du-Thanh, A | 1 |
| Terrail, N | 1 |
| Dandurand, M | 1 |
| Dereure, O | 1 |
| Soares, R | 1 |
| Kupa, LVK | 1 |
| Arnone, M | 1 |
| Pedrosa, TDN | 1 |
| Silva, CAAD | 1 |
| Jalenques, I | 1 |
| Rondepierre, F | 1 |
| Massoubre, C | 1 |
| Bonnefond, S | 1 |
| Schwan, R | 1 |
| Labeille, B | 1 |
| Perrot, JL | 1 |
| Collange, M | 1 |
| Mulliez, A | 1 |
| D'Incan, M | 1 |
| Nutan, F | 1 |
| Ortega-Loayza, AG | 1 |
| Chasset, F | 3 |
| Tounsi, T | 1 |
| Cesbron, E | 2 |
| Barbaud, A | 2 |
| Francès, C | 6 |
| Arnaud, L | 2 |
| Jachiet, M | 1 |
| Cordel, N | 2 |
| Bouaziz, JD | 1 |
| Bagot, M | 1 |
| Bishnoi, A | 1 |
| Singh, V | 1 |
| Handa, S | 1 |
| Vinay, K | 1 |
| Groenen, PS | 1 |
| van Helmond, N | 1 |
| Chapman, KB | 1 |
| Dalm, VA | 1 |
| van Hagen, PM | 1 |
| Zattra, E | 1 |
| Stan, R | 1 |
| Russo, I | 1 |
| Lo Nigro, A | 1 |
| Peserico, A | 1 |
| Alaibac, M | 1 |
| Okon, L | 1 |
| Rosenbach, M | 2 |
| Krathen, M | 2 |
| Rose, M | 1 |
| Propert, K | 1 |
| Okawa, J | 2 |
| Werth, V | 1 |
| Baret, I | 1 |
| De Haes, P | 1 |
| Anyanwu, CO | 1 |
| Stewart, CL | 1 |
| Werth, VP | 5 |
| Hejazi, EZ | 1 |
| Kindle, SA | 1 |
| Wetter, DA | 1 |
| Davis, MD | 1 |
| Pittelkow, MR | 1 |
| Sciallis, GF | 1 |
| Wang, D | 1 |
| Chen, H | 1 |
| Wang, S | 1 |
| Zou, Y | 1 |
| Li, J | 1 |
| Pan, J | 1 |
| Ren, T | 1 |
| Zhang, Y | 1 |
| Chen, Z | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Fennira, F | 1 |
| Soubrier, M | 1 |
| Petit, A | 1 |
| Wu, EY | 1 |
| Schanberg, LE | 1 |
| Wershba, EC | 1 |
| Rabinovich, CE | 1 |
| Kuhn, A | 2 |
| Aberer, E | 1 |
| Bata-Csörgő, Z | 1 |
| Caproni, M | 1 |
| Dreher, A | 1 |
| Gläser, R | 1 |
| Klötgen, HW | 1 |
| Landmann, A | 1 |
| Marinovic, B | 1 |
| Nyberg, F | 1 |
| Olteanu, R | 1 |
| Ranki, A | 1 |
| Szepietowski, JC | 1 |
| Volc-Platzer, B | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Ruland, V | 1 |
| Bonsmann, G | 1 |
| Chang, AY | 1 |
| Braunstein, I | 1 |
| Goodman, NG | 1 |
| Shah, A | 1 |
| Kovarik, CL | 1 |
| Luning Prak, E | 1 |
| Cortés-Hernández, J | 2 |
| Torres-Salido, M | 1 |
| Castro-Marrero, J | 1 |
| Vilardell-Tarres, M | 2 |
| Ordi-Ros, J | 2 |
| Ávila, G | 1 |
| Thomson, KF | 1 |
| Goodfield, MJ | 1 |
| Bohmeyer, J | 1 |
| Achenbach, A | 1 |
| Westenberger, M | 1 |
| Stadler, R | 1 |
| Crouch, RB | 1 |
| Foley, PA | 1 |
| Ng, JC | 1 |
| Baker, CS | 1 |
| Housman, TS | 1 |
| Jorizzo, JL | 1 |
| McCarty, MA | 1 |
| Grummer, SE | 1 |
| Fleischer, AB | 2 |
| Sutej, PG | 1 |
| Barete, S | 1 |
| Ayoub, N | 1 |
| Piette, JC | 2 |
| Pelle, MT | 1 |
| Briani, C | 2 |
| Zara, G | 3 |
| Rondinone, R | 3 |
| Della Libera, S | 1 |
| Ermani, M | 3 |
| Ruggero, S | 2 |
| Ghirardello, A | 2 |
| Zampieri, S | 2 |
| Doria, A | 3 |
| Callen, JP | 1 |
| Heath, M | 1 |
| Raugi, GJ | 1 |
| Cuadrado, MJ | 1 |
| Karim, Y | 1 |
| Sanna, G | 1 |
| Smith, E | 1 |
| Khamashta, MA | 2 |
| Hughes, GR | 2 |
| Groves, RW | 1 |
| Gambini, D | 1 |
| Carrera, C | 1 |
| Passoni, E | 1 |
| Muratori, S | 1 |
| Berti, E | 1 |
| Caputo, R | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| Wenzel, J | 1 |
| Bieber, T | 1 |
| Uerlich, M | 1 |
| Tüting, T | 1 |
| Iaccarino, L | 1 |
| Toffanin, E | 1 |
| Sarzi-Puttini, P | 1 |
| Lyakhovisky, A | 1 |
| Baum, S | 1 |
| Shpiro, D | 1 |
| Salomon, M | 1 |
| Trau, H | 1 |
| Llambrich, A | 1 |
| Romero, D | 1 |
| Iranzo, P | 1 |
| Segura, S | 1 |
| Moreno, JA | 1 |
| Herrero, C | 1 |
| Sharma, NL | 1 |
| Sharma, VC | 1 |
| Mahajan, VK | 1 |
| Shanker, V | 1 |
| Ranjan, N | 1 |
| Gupta, M | 1 |
| Arienti, S | 1 |
| Stevens, RJ | 1 |
| Andujar, C | 1 |
| Edwards, CJ | 1 |
| Ames, PR | 1 |
| Barwick, AR | 1 |
| Rúa-Figueroa, I | 1 |
| Erausquin, C | 1 |
| Naranjo, A | 1 |
| Carretero-Hernández, G | 1 |
| Rodriguez-Lozano, C | 1 |
| De la Rosa, P | 1 |
| Duong, DJ | 1 |
| Spigel, GT | 1 |
| Moxley, RT | 1 |
| Gaspari, AA | 1 |
| Flageul, B | 1 |
| Wallach, D | 1 |
| Cavelier-Balloy, B | 1 |
| Bachelez, H | 1 |
| Carsuzaa, F | 1 |
| Dubertret, L | 1 |
| Calabrese, L | 1 |
| Walchner, M | 1 |
| Meurer, M | 1 |
| Plewig, G | 1 |
| Messer, G | 1 |
| Versapuech, J | 1 |
| Beylot-Barry, M | 1 |
| Doutre, MS | 1 |
| Beylot, C | 1 |
| McCauliffe, DP | 1 |
| Sbai, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus[NCT00633945] | 5 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus[NCT01408199] | Phase 4 | 15 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Cutaneous Lupus Area and Severity Index (CLASI); range of disease activity is 0-70. Lower scores reflect less activity. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 0 weeks | 6 weeks | 12 weeks | 52 weeks | |
| Lenalidomide | 21.4 | 10.8 | 8.6 | 5.3 |
Fatigue scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no fatigure and 10 to fatigue as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 7.25 | 3.4 | 5.25 | 3 |
Itch scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no itch and 10 to itch as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 4.0 | 1.2 | 2.25 | 0 |
CXCL10, an interferon-inducible chemokine, and immunophenotyping by immunostaining. Measurement of interferon-inducible genes from peripheral blood mononuclear cells before and after treatment. (NCT00633945)
Timeframe: 6 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| IFN score decrease | CD4 decrease | |
| Lenalidomide Nonresponder | 1 | 1 |
| Lenalidomide Responders | 4 | 4 |
Pain in skin was recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no pain and 10 to pain as bad as you can imagine. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 4.5 | 2 | 2.5 | 0.5 |
General skin scores were recorded by the patient on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 5.6 | 3.6 | 4.2 | 0.8 |
General skin scores were recorded on a 10 cm visual analogue scale at each visit. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health. (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 6 | 3 | 3.8 | 2 |
"Skindex function scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of function impact on QoL is scored as 20 (this is represented as a 1 on the 1-5 scale. The worst impact of function on QoL is 100. This is represented as a 5 on the 1-5 scale." (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 41.26 | 30.42 | 29.2 | 4.2 |
"Skindex symptoms scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of symptom impact on QoL is scored as 20 (this is represented as a 1 on the 1-5 scale. The worst impact of symptoms on QoL is 100. This is represented as a 5 on the 1-5 scale." (NCT00633945)
Timeframe: Weeks 0 through 52
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| week 0 | week 6 | week 12 | week 52 | |
| Lenalidomide | 58.5 | 41.82 | 36.4 | 12.5 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
15 reviews available for thalidomide and Lupus Erythematosus, Cutaneous
| Article | Year |
|---|---|
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Retrospective S | 2021 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Hum | 2017 |
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Peripheral Nervous System Diseases | 2018 |
TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
Topics: Animals; Antibodies, Blocking; Clinical Trials as Topic; Drug Resistance; Drug-Related Side Effects | 2013 |
Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment.
Topics: Administration, Topical; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Cytokines; G | 2016 |
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murin | 2011 |
Treatment of cutaneous lupus.
Topics: Administration, Topical; Antimalarials; Calcineurin Inhibitors; Dapsone; Glucocorticoids; Humans; Im | 2011 |
Thalidomide in cutaneous lupus erythematosus.
Topics: Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Lupus Eryth | 2003 |
Update on the management of cutaneous lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antimalarials; Dermatologic Agents; Evidence-Based Medicine; Humans; Lupus | 2004 |
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladrib | 2004 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
[Systemic treatment of cutaneous lupus erythematosus].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antimal | 2003 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Cutaneous lupus erythematosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Biopsy; Clofazimine; Dermatologic Agents; Di | 2001 |
4 trials available for thalidomide and Lupus Erythematosus, Cutaneous
| Article | Year |
|---|---|
Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Topics: Administration, Oral; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule | 2014 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalid | 2012 |
Thalidomide: an experience in therapeutic outcome and adverse reactions.
Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen | 2007 |
American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus.
Topics: Adult; Clinical Protocols; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Midd | 1999 |
39 other studies available for thalidomide and Lupus Erythematosus, Cutaneous
| Article | Year |
|---|---|
Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous.
Topics: Aged; Costs and Cost Analysis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lup | 2022 |
Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Topics: Child; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Ery | 2023 |
Apremilast for the Treatment of Concomitant Subacute Cutaneous Lupus Erythematosus and Psoriasis.
Topics: Humans; Lupus Erythematosus, Cutaneous; Psoriasis; Thalidomide | 2022 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thal | 2023 |
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Thalidomide; Treatment Outcome | 2021 |
One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
Topics: Adult; Female; Humans; Incidence; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Mal | 2021 |
High Prevalence of Personality Disorders in Skin-restricted Lupus Patients.
Topics: Adult; Age of Onset; Case-Control Studies; Chi-Square Distribution; Dermatologic Agents; Female; Fra | 2017 |
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.
Topics: Adult; Age Distribution; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration | 2018 |
Thalidomide and thromboprophylaxis for dermatologic indications: An unmet need for more evidence.
Topics: Drug Tolerance; Humans; Lupus Erythematosus, Cutaneous; Multiple Myeloma; Thalidomide; Venous Thromb | 2018 |
Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation.
Topics: Electric Stimulation Therapy; Female; Ganglia, Spinal; Humans; Immunosuppressive Agents; Lupus Eryth | 2019 |
Efficacy of lenalidomide in refractory lupus pernio.
Topics: Chilblains; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalid | 2013 |
Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
Topics: Adult; Aged; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Recurrence; Retrospe | 2015 |
Thalidomide-induced orofacial neuropathy.
Topics: Adult; Face; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Paresthesia; | 2014 |
Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Topics: Academic Medical Centers; Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Coho | 2016 |
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Topics: Adolescent; Adult; Blood Sedimentation; China; Constipation; Dose-Response Relationship, Drug; Exant | 2016 |
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Topics: Adult; Chronic Disease; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cuta | 2016 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus | 2017 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Daps | 2017 |
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Topics: Adult; Female; Humans; Lenalidomide; Leukocytes; Lupus Erythematosus, Cutaneous; Lupus Erythematosus | 2012 |
Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Humans; Long-Term Care; Lupus Erythematosus, Cu | 2012 |
Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cut | 2001 |
[Thalidomide therapy of cutaneous lupus erythematosus].
Topics: Adult; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Intrader | 2002 |
Thalidomide experience of a major Australian teaching hospital.
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Dermatologic Agents; Female; Humans; Lupus Erythematosus, | 2002 |
Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosu | 2003 |
[Classification of dermatologic manifestations in lupus erythematosus].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Antimalarials; Clinical Trials as Topic; Dapsone; Dermato | 2003 |
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
Topics: Adult; Electrophysiology; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle A | 2004 |
Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressi | 2005 |
Thalidomide.
Topics: Humans; Lupus Erythematosus, Cutaneous; Thalidomide | 2004 |
Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.
Topics: Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Thalidomide | 2004 |
Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
Topics: Adult; Dose-Response Relationship, Drug; Electrophysiology; Female; Humans; Immunosuppressive Agents | 2005 |
[Thalidomide therapy for discoid lupus erythematosus].
Topics: Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Retrospective | 2006 |
Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide.
Topics: Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle Aged; Myocardial In | 2007 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
Topics: Adult; Drug Tolerance; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Nervous Sy | 1997 |
Pustuloderma during cutaneous lupus treatment with thalidomide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Drug Eruptions; Female; Humans; | 1999 |
[Thalidomide and thrombosis].
Topics: Adult; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; | 2000 |
Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; C-Reactive Protein; Complement System Proteins; Enzyme-Linked Immuno | 2000 |
[Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases].
Topics: Adult; Aged; Antimalarials; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Mal | 2000 |
Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus.
Topics: Humans; Lupus Erythematosus, Cutaneous; Risk Assessment; Thalidomide; Thrombosis | 2002 |